字号·· | 护眼
路透社

美国FDA批准拜耳抗凝血药用于预防中风复发US FDA approves Bayer's blood thinner to prevent repeat strokes

点「原文对照」整页切到原文,或双击某段只看那段的原文。

2023年9月23日,德国勒沃库森化工工业园区“Chempark”外,可以看到由1710个LED玻璃灯泡组成的120米高拜耳十字标志。这是德国制药和化工企业拜耳集团的标志。路透社/沃尔夫冈·拉泰/资料照片The 120 metres high Bayer Cross, logo of German pharmaceutical and chemical maker Bayer AG, consisting of 1710 LED glass bulbs is seen outside the industrial park "Chempark" of the chemical industry in Leverkusen, Germany, September 23, 2023. REUTERS/Wolfgang Rattay/File Photo

美国食品药品监督管理局(FDA)周一批准了一种由拜耳(BAYGn.DE)开发的新型抗凝血药,用于预防曾经中风或发生过“小中风”患者的再次中风。这种药物的化学名称为阿苏德西安(asundexian),将以“Sunharbo”作为商品名销售,是首个获批通过阻断凝血蛋白因子XIa来预防有害血栓形成的治疗药物。目前畅销的抗血栓药物,如辉瑞(PFE.N)和百时美施贵宝(BMY.N)的艾乐妥(Eliquis),以及强生(JNJ.N)和拜耳销售的利伐沙班(Xarelto),均通过阻断因子Xa发挥作用,后者是参与血栓形成的另一种蛋白。

By Sneha S K, Michael Erman The US Food and Drug Administration on Monday approved a new type of blood thinner developed by Bayer (BAYGn.DE) for the prevention of strokes in patients who have already had one or have had a "mini-stroke." The drug, which has the chemical name asundexian and will be sold under the brand name Sunharbo, is the first approved treatment designed to prevent harmful blood clots by blocking the clotting protein Factor XIa. Current big-selling blood-clot preventers, such as Pfizer (PFE.N) and Bristol Myers Squibb's (BMY.N) Eliquis and Xarelto, sold by Johnson & Johnson (JNJ.N) and Bayer, work by blocking Factor Xa, a different protein involved in the formation of blood clots.

Sunharbo获批作为一种每日一次的治疗药物,用于预防既往中风非由心源性血栓引起的患者再次中风。它也获批用于经历过高风险短暂性脑缺血发作(通常称为“小中风”)的患者。中风是美国主要的死亡原因之一,拜耳估计,美国每年约有79.5万人可能经历中风。

Sunharbo is approved as a once-daily treatment to prevent another stroke in patients whose previous stroke was not caused by a clot from the heart. It is also approved for patients who have had a high-risk transient ischemic attack, often called a "mini-stroke." Stroke is a leading cause of death in the United States, and Bayer estimates that each year approximately 795,000 people in the US are likely to experience a stroke.

拜耳押注该药物将有助于抵消老牌大卖药收入下滑的影响,例如利伐沙班在失去专利保护后面临来自更便宜仿制药的竞争。

Bayer is betting on the drug to help offset declining revenue from older blockbuster medicines, such as Xarelto, which has faced competition from cheaper generics after losing patent protection.

拜耳美国业务总裁塞巴斯蒂安·古特(Sebastian Guth)在接受采访时表示:“我们认为,我们正在为市场带来一种改变临床实践的创新。”

"We believe that we're bringing a practice-changing innovation to the market," Sebastian Guth, president of Bayer's US operations, said in an interview.

古特说:“过去20年里,中风复发率没有任何变化,因此对这种药物存在真实且非常重大的期待。”

"There have not been any changes in the recurrence rates of stroke over the past 20 years, so there's a genuine and very significant excitement" for the drug, Guth said.

公司此前曾将该药物描述为具有“大卖药潜力”,通常意味着年销售额至少10亿美元。古特表示,阿苏德西安将成为公司未来成功的重要组成部分。中国药品监管部门上个月底批准了 Sunharbo。

The company has previously described the drug as having blockbuster potential, which typically means at least $1 billion in annual sales. Guth said asundexian would be an important part of the company's future success. The approval was based on data from a late-stage study that showed the drug reduced both the frequency and severity of recurrent ischemic strokes, which are caused by clogged arteries.

该批准基于一项晚期临床研究的数据,数据显示该药物降低了复发性缺血性卒中的发生频率和严重程度,缺血性卒中是由动脉堵塞引起的。

China's drug regulator approved Sunharbo late last month.

其他正在研发、未来可能与 Sunharbo 竞争的药物包括诺华的 abelacimab 以及百时美施贵宝与强生联合开发的 milvexian,这两款药物均尚未公布晚期卒中预防数据。

Other drugs in development that could eventually compete with Sunharbo include Novartis' (NOVN.S) abelacimab and milvexian, a joint effort by Bristol Myers and J&J, both of which have yet to report late-stage stroke-prevention data.

阅读媒体原文 ↗